Chronic myeloid leukemia, version 1.2019, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient's age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
mRNA expression-based diagnostics are now part of clinical CML diagnostics.
“Although previously debated, mRNA expression-based diagnostics have entered clinical CML diagnostics (45).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 150 · Cited by 277
Part of this paper’s reference list could not be split into single entries.
Research works printed but not linked: 7
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30.
- Deininger MW, Kopecky KJ, Radich JP, et al. Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol 2014;164:223-232.
- Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814-818.
- Landstrom AP, Ketterling RP, Knudson RA, Tefferi A. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma 2006;47:2055-2061.
- Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014;124:511-518.
- Iriyama N, Fujisawa S, Yoshida C, et al. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group. Am J Hematol 2015;90:282-287.
- Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634- 1642.
- Authors
- Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., Bhatnagar, B., Curtin, P., DeAngelo, D. J., Gotlib, J., Hobbs, G., Jagasia, M., Kantarjian, H. M., Maness, L., Metheny, L., Moore, J. O., Pallera, A., Pancari, P., Patnaik, M., Purev, E., Rose, M. G., Shah, N. P., Smith, B. D., Snyder, D. S., Sweet, K. L., Talpaz, M., Thompson, J., Yang, D. T., Gregory, K. M., & Sundar, H.
- Affiliations
- Seattle Cancer Care Alliance (US)
- University of Colorado Cancer Center (US)
- Fox Chase Cancer Center (US)
- Duke University (US)
- University of Utah (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Radich, Jerald P.
- Deininger, Michael
- Abboud, Camille N.
- Altman, Jessica K.
- Berman, Ellin
- Bhatia, Ravi
- Bhatnagar, Bhavana
- Curtin, Peter
- DeAngelo, Daniel J.
- Gotlib, Jason
- Hobbs, Gabriela
- Jagasia, Madan
- Kantarjian, Hagop M.
- Metheny, Leland
- Patnaik, Mrinal
- Shah, Neil P.
- Smith, B. Douglas
- Sweet, Kendra L.
- Talpaz, Moshe
- Thompson, James
- Yang, David T.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2018-09
- Volume
- 16
- Issue
- 9
- Pages
- 1108-1135
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2891716460
- Cited by
- 277
- References
- 150
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 14 · 2023: 17 · 2022: 22 · 2021: 49 · 2020: 65 · 2019: 57 · 2018: 13 · 2017: 22 · 2016: 5 · 2015: 1
- FWCI
- 32.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of the National Comprehensive Cancer Network (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- chronic myeloid leukemia, Philadelphia chromosome, BCR-ABL fusion gene, tyrosine kinase inhibitors, chronic phase CML, accelerated phase, blast crisis, risk stratification, first-line therapy, diagnosis
- MeSH terms
- Progression-Free Survival, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow, Clinical Trials as Topic, Dose-Response Relationship, Drug, Humans, Medical Oncology, Philadelphia Chromosome, Prognosis, Societies, Medical, Biomarkers, Tumor, United States, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Disease Progression, Risk Assessment, Patient Selection, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
